Editing Baytril


This antibiotic is widely used in veterinary medicine as an antibacterial agent, showing high activity against both Gram-negative and Gram-positive bacteria
Enrofloxacin, sold under the brand name Baytril, among others, is a fluoroquinolone antibiotic used for the treatment of animals. It is a bactericidal agent. The bactericidal activity of enrofloxacin is concentration-dependent, with susceptible bacteria cell death occurring within 20–30 minutes of exposure. 



Pregnancy category: AU: B3
Metabolism: Kidney and non-kidney
Excretion: Bile duct (70%); kidney (30%)
AHFS/Drugs.com: International Drug Names
ATCvet code: QJ01MA90 (WHO) QD06BA51 (WHO)
Bioavailability: 80% in dogs, 65-75% in sheep
Elimination half-life: 4–5 hours in dogs, 6 hours in cats, 1.5 - 4.5 hours in sheep




== Enrofloxacin uses and doses in Rabbits==


===Pasteurella Protocol ===
as been use for  Pasteurella and respiratory issues, it more frequently masks of Pasteurella symptoms then cures. Baytril is a Broad spectrum Antibiotic so can be used to treat a wide range of issues, it is stronger then LA 200. 
Broome RL, Brooks DL. Efficacy of enrofloxacin in the treatment of respiratory pasteurellosis in rabbits. Lab Anim Sci 1991;41:572-576.

Baytril has also been effective to treat  early onset cases in trials 2014.
 
https://bmcvetres.biomedcentral.com/articles/10.1186/s12917-014-0276-6
Alternative treatment of serious and mild Pasteurella multocida infection in New Zealand White rabbits
Orsolya Palócz, János Gál, Paul Clayton, Zoltán Dinya, Zoltán Somogyi, Csaba Juhász & György Csikó 
BMC Veterinary Research volume 10, Article number: 276 (2014)
 
 Pasteurella multocida causes numerous economically relevant diseases in livestock including rabbits. Immunization is only variably effective. Prophylactic 
 antibiotics are used in some species but are contra-indicated in rabbits, due to their adverse effects on the rabbit microbiota. There is therefore a substantial 
 need for alternative forms of infection control in rabbits; we investigated the effect of oral β-glucan on P. multocida infection in this species.

 Results
 Thirty-five New Zealand White rabbits were randomly divided into five groups of seven animals. Three groups were inoculated with Pasteurella multocida 
 intranasally (in.), a physiologically appropriate challenge which reproduces naturally acquired infection, and received either (1-3), (1-6) β-glucans or placebo. 
 Four other groups were inoculated both in. and intramuscularly (im.), representing a supra-physiological challenge, and received either (1-3), (1-6) β-glucans, 
 antibiotic or placebo. β-glucans given prophylactically were highly effective in protecting against physiological (in.) bacterial challenge. They were less 
 effective in protecting against supra-physiological bacterial challenge (in. and im.), although they extended survival times. This latter finding has practical 
 relevance to breeders as it extends the window in which heavily infected and symptomatic animals can be salvaged with antibiotics.

 Conclusions
 In our study, (1-3), (1-6) β-glucans were highly effective in protecting against a model of naturally acquired P. multocida infection and extended survival times 
 in the supra-physiological model. Enrofloxacin(baytril) was effective in protecting against supra-physiological infection. We are currently reviewing the use of combined 
 prophylaxis.



===GI stasis protocol===
•	Use only when indicated; enrofloxacin or trimethoprim/sulfa are generally the drugs of choice; use parenterally until stools are passed; metronidazole may be indicated for anaerobe overgrowth

*Broome RL, Brooks DL, Babish JG, et al. Pharmacokinetic properties of enrofloxacin in rabbits. Am J Vet Res 1991;52:1835-1841.
*Cabanes A, Arboix M, Anton JMG, et al. Pharmacokinetics of enrofloxacin after intravenous and intramuscular injection in rabbits. Am J Vet Res 1992;53:2090-2093.
*Elmas M, Uney K, Yazar E, et al. Pharmacokinetics of enrofloxacin following intravenous and intramuscular administration in Angora rabbits. Res Vet Sci 2007;82:242-245.

==Drug class:== 




==Dose:==
Enrofloxacinb (Baytril, Bayer)   

Dosage:

200 mg/L drinking water  14 days

5 mg/kg IM, IV q12-24h44       Angora rabbits/PD

5 mg/kg PO, SC, IM, IV  PD;19,23 clinical trial for pasteurellosis,  14 days

5-10 mg/kg PO, SC, IM q12h  Pasteurellosis

5-20 mg/kg PO, IM q12h 3 14-30 days     Pasteurellosis

==Indications:==


==Side Effects==


==During Pregnancy or Nursing==
.

==Patient Tips==

==Drug Interactions==

==Compare Alternatives==


==notes==
May cause arthropathies in young dogs, but similar effects using standard dosages in rabbits have not been reported; SC and IM injections may cause muscle necrosis or sterile abscesses; dilute before giving parenterally






==References==
Exotic animal formulary / editor, James W. Carpenter ; associate editor, Christopher J. Marion. -- 4th ed.  p. ; cm. 
ISBN 978-1-4377-2264-2 (pbk.) I. Carpenter, James W. (James Wyman). II. Marion, Christopher J. 
[DNLM: 1. Veterinary Drugs--Formularies. 2. Animals, Domestic--Formularies. 3. Animals,  Wild--Formularies. 4. Animals, Zoo--Formularies. 5. Drug Therapy--veterinary--Formularies. SF 917]
@@ Line 5: / Line 5: @@
-*Pregnancy category: AU: B3
+Pregnancy category: AU: B3
-*Metabolism: Kidney and non-kidney
+Metabolism: Kidney and non-kidney
-*Excretion: Bile duct (70%); kidney (30%)
+Excretion: Bile duct (70%); kidney (30%)
-*AHFS/Drugs.com: International Drug Names
+AHFS/Drugs.com: International Drug Names
-*ATCvet code: QJ01MA90 (WHO) QD06BA51 (WHO)
+ATCvet code: QJ01MA90 (WHO) QD06BA51 (WHO)
-*Bioavailability: 80% in dogs, 65-75% in sheep
+Bioavailability: 80% in dogs, 65-75% in sheep
-*Elimination half-life: 4–5 hours in dogs, 6 hours in cats, 1.5 - 4.5 hours in sheep
+Elimination half-life: 4–5 hours in dogs, 6 hours in cats, 1.5 - 4.5 hours in sheep
-*Antimicrobial Agents Used in Rabbits